Healthcare >> CEO Interviews >> March 8, 2004

EDWARD RUDNIC – ADVANCIS PHARMACEUTICAL CORPORATION (AVNC)

EDWARD M. RUDNIC founded Advancis Pharmaceutical Corporation and has been the President, Chief Executive Officer and a Director since its inception. Dr. Rudnic has more than 20 years of industry experience in the development and commercialization of a wide range of pharmaceutical products. He has filed over 30 patents (US and Internationally), primarily in the fields of antibiotics, antibiotic combinations and antibiotic adjuvants, as well as in the antifungal, antiviral and anti- cancer fields. From April 1991 to January 1996, Dr. Rudnic directed the Research and Development activities in the US for Shire Pharmaceuticals. Shire acquired Pharmavene in 1997, a startup company focused on the design and commercialization of drug delivery systems, where he was Senior Vice President for Development and Technical Operations from January 1996 to January 1999. From March 1985 to October 1990, he held positions of increasing responsibility as a Director of Formulation Development and head of Pharmaceutical Process Development at Schering- Plough Corporation. Dr. Rudnic was a Research Investigator at E.R. Squibb and Sons, developing oral controlled-release dosage forms and novel drug delivery concepts. Dr. Rudnic has a BS in Pharmacy, an MS in Pharmaceutics and a Doctorate in Pharmaceutical Sciences from the University of Rhode Island. He holds Adjunct Professorships at the University of Rhode Island and the University of Maryland. Profile
TWST: Please give us an overview of Advancis Pharmaceutical Corporation

and explain your technology to us.

Dr. Rudnic: Advancis is a company that has been working diligently over

the past four